Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis and treatment of deep vein thrombosis (DVT),Prophylaxis and treatment of pulmonary embolism (PE),Anticoagulation for atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, myocardial infarction),Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is dose-dependent: 0.5–1.5 hours after intravenous administration of 100 U/kg, increasing to 1.5–2.5 hours after 200 U/kg, and up to 3–6 hours after 400 U/kg. Clinically, the anticoagulant effect (a PTT) has a half-life of approximately 1–2 hours, and this is used for dosing adjustments.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Heparin is primarily cleared via the reticuloendothelial system and undergoes desulfation and depolymerization. A portion is excreted unchanged in urine.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: Heparin is primarily cleared by the reticuloendothelial system and the liver via desulfation and depolymerization, with metabolites excreted in urine. Only about 50% of an administered dose is excreted unchanged in urine at therapeutic doses; the remainder is metabolized. Biliary/fecal excretion is minimal.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Heparin binds extensively to various plasma proteins, including antithrombin III (high affinity), albumin, and other proteins. Overall protein binding is approximately 95%.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.06–0.07 L/kg (low, as heparin is largely confined to the intravascular space).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Subcutaneous: approximately 30–40% (low due to poor absorption and metabolism at injection site). Intravenous: 100%.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific GFR-based dose adjustment required; monitor a PTT. In severe renal impairment (Cr Cl <30 m L/min), reduce infusion rate by 20-50% and monitor anti-Xa levels.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% with close a PTT monitoring. Child-Pugh Class C: Avoid or use with extreme caution; reduce dose by 50-75%.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
IV bolus: 50-100 units/kg, then continuous IV infusion: 15-25 units/kg/hour. Titrate to a PTT 60-85 seconds or anti-Xa 0.3-0.7 units/m L.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients may have reduced clearance; use lower initial infusion rates (e.g., 750 units/hour) and monitor a PTT frequently. Start with 50% of the usual bolus dose in patients >70 years.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Heparin is not intended for intramuscular use due to risk of hematoma. Monitor for signs of bleeding, especially in patients with risk factors. Epidural or spinal hematomas may occur with concurrent neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hemorrhage: monitor coagulation parameters (a PTT) and adjust dose accordingly.,Heparin-induced thrombocytopenia (HIT): monitor platelet counts; discontinue if HIT suspected.,Hyperkalemia: heparin suppresses aldosterone synthesis; monitor potassium in high-risk patients.,Osteoporosis with long-term use ( >3 months).,Use with caution in patients with severe hepatic or renal impairment, uncontrolled hypertension, or history of gastrointestinal ulcers.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Active major bleeding (e.g., intracranial, gastrointestinal, retroperitoneal),History of heparin-induced thrombocytopenia (HIT),Severe thrombocytopenia (platelet count <100,000/µL),Hypersensitivity to heparin or porcine products,Known coagulation disorders (e.g., hemophilia, von Willebrand disease),Inability to perform appropriate coagulation monitoring (e.g., a PTT)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. However, avoid excessive alcohol consumption as it may increase bleeding risk. Vitamin K-rich foods (e.g., leafy greens) do not affect heparin's anticoagulant effect, in contrast to warfarin.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk of major malformations. Second and third trimesters: No known teratogenic effects; use for treatment or prevention of thrombosis is considered safe. Risk of maternal hemorrhage and placental abruption exists with overdose.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Heparin is not excreted into breast milk due to its high molecular weight and negative charge, making it compatible with breastfeeding. M/P ratio is not applicable as it is undetectable in milk.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy is associated with increased plasma volume, renal clearance, and heparin-binding proteins, which may reduce heparin efficacy. Dose adjustment is often required: a PTT monitoring is mandatory, and doses are typically increased (up to 30-50% higher) to maintain therapeutic levels. Weight-based dosing should account for actual body weight. Postpartum, doses may need reduction due to normalization of clearance.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Use actual body weight for dosing; check a PTT 6 hours after initiation and after dose changes; monitor platelet count for heparin-induced thrombocytopenia (HIT); avoid intramuscular injections during therapy. Protamine sulfate (1 mg per 100 units heparin) reverses effects. For I. V. flushes, use preservative-free formulation when possible.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers (including dentists) that you are on heparin.,Do not take any new medications without consulting your doctor.,Seek medical help if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting coagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Adult: IV bolus 5,000 units followed by continuous IV infusion at 1,000 units/hour (25,000-40,000 units/24h) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin is not known to cross the placenta due to its high molecular weight and negative charge, and is not associated with fetal teratogenicity. First trimester: No increased risk. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.